2014-06-29

[DIV28SUPER] NIDA Neuroscience Update June 30, 2014

Table of contents:

I.    Frontiers in Addiction Research Mini-convention

II.   Short Course on the Genetics of Addiction http://courses.jax.org/2014/addiction.html

III.  Psychiatric Genetics Consortium (PGC) Addiction Subgroup Web Conference Tuesday, July 8th from 11-12PM EST, minus 5 Hours GMT. 

IV.  Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Administrative Supplement) (FOA) Number: PA-14-249

V.   NIDA's Cutting Edge Basic Research Awards (CEBRA R21) CEBRA PAR-12-086

VI. . Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM)  (R21/R33)     PAR-13-350

 

------------------------------

 

I. Frontiers in Addiction Research Mini-convention – The National Institute on Drug Abuse is pleased to present its annual Frontiers in Addiction Research Mini-convention, a satellite event of the Society for Neuroscience Annual Meeting.  The NIDA mini-convention will take place on November 14, 2014 from 8:00 am - 5:50 pm in the Natcher Auditorium on the National Institutes of Health Campus in Bethesda, MD. 

 

The NIDA Mini-convention provides a forum for presentation on contemporary topics in the areas of neuroscience and addiction research.  It includes four scientific symposia, keynote presentations by the 2013 and 2014 winners of the SfN Jacob P. Waletzky Award which recognizes excellence in research in the area of substance abuse and the brain and nervous system, and a poster session showcasing the work of early career investigators.  The 2014 symposia are listed below.  Additional information on the 2014 mini-convention, including registration information can be found at:  http://www.seiservices.com/nida/frontiers2014/Default.aspx.

 

·         Emerging and Novel Aspects of Neuronal Transmission

·         Extracellular RNAs in Neuroscience:  Biology, Biomarkers, and Therapeutics

·         Advances in High Resolution and Large Scale Imaging of Brain Networks and Circuits

·         The Effect of Drug-, Stress-, and Pain-induced Neuroinflammation on Glymphatics and Sleep

 

-------------------------

 

II. Short Course on the Genetics of Addiction http://courses.jax.org/2014/addiction.html

Limited scholarships may be available to help attendees with travel expenses

 

Aug 28 - Sep 2 | The Jackson Laboratory - Bar Harbor, ME

 

This course emphasizes genetic applications and approaches to drug addiction research through methodological instruction based on literature, data sets and informatics resources drawn from studies of addiction related phenotypes. The course includes plenary sessions on major progress in addiction genetics, and discussion sessions in which students present their work for discussion on applications of genetic methods. Students will leave the course able to design and interpret genetic and genomic studies of addiction as they relate to their specific research question, and will be able to make use of current bioinformatics resources to identify research resources and make use of public data sources in their own research. 

 

-----------------------------

 

III. Psychiatric Genetics Consortium (PGC) Addiction Subgroup Web Conference Tuesday, July 8th from 11-12PM EST, minus 5 Hours GMT. 

 

If you have human genetics data relevant to substance abuse and co-morbid disorders, we welcome your participation in the web conference to be held Tuesday, July 8th from 11-12PM EST, minus 5 Hours GMT.  The purpose of the consortium is to combine data and analytics to increase power for detecting gene variants associated with addiction to various substances.

 

Agenda:

Introductions & opening remarks:  Joni Rutter

PGC Addictions group:  Arpana Agrawal;, Joel Gelernter, Howard Edenberg

Discussion/Questions:  Group (moderated by Jonathan Pollock)

Next steps:  Arpana Agrawal, Joel Gelernter, Howard Edenberg and Joni Rutter

 

We hope that you will join the call to learn how to get involved.

The call-in and webex information is below:

 

Topic: Introduction to the Psychiatric Genetics Consortium Addictions Work Group
Date and Time: Tuesday, July 8, 2014 10:30 am, Eastern Daylight Time (New York, GMT-04:00)
Event number: 666 125 416
Event password: Success1

-------------------------------------------------------
To join the online meeting
-------------------------------------------------------
At least 30 minutes before the starting time:

1. Go to
https://nida-events.webex.com/nida-events/onstage/g.php?d=666125416&t=a
2. If requested, enter your name and email address.
3. If a password is required, enter the meeting password: Success1
4. Click "Join".

-------------------------------------------------------
Telephone conference information for (Audio)
-------------------------------------------------------
Telephone #: 18666798219
Passcode: 9680216#


For more information contact

Mark S. Caulder, MS, MPH
Health Program Specialist for Population and Applied Genetics

Division of Basic Neuroscience and Behavioral Research
National Institute on Drug Abuse
National Institutes of Health
6001 Executive Blvd.
Bethesda, MD 20892-9555

Tel: 301.435.1308
Fax: 301.594.6043
Email: caulderm@mail.nih.gov

-------------------------------------------

IV. Administrative Supplements for the U.S.-Japan Brain Research Cooperative Program (BRCP) - U.S. Entity (Administrative Supplement) (FOA) Number: PA-14-249

Purpose: The National Institutes of Health (NIH) announces the continuation of the U.S. entity of the U.S.-Japan Brain Research Cooperative Program (BRCP). This administrative supplement program will provide funds to research projects that are currently supported by the participating NIH Institutes and Centers. The purpose of the BRCP is to promote scientist exchange, training, and collaborations in basic, translational and clinical research between neuroscientists from the U.S. and Japan. The U.S. entity of the BRCP supports the following activities:

1) Visit of U.S. scientists to conduct collaborative research and/or to acquire advanced research skills in Japanese institutions,

2) Joint workshops to exchange scientific information and to foster collaborations.

Application Due Date(s): September 2, 2014; September 2, 2015; September 2, 2016

NIDA specific interest: The NIDA supports basic, clinical, and applied research on the causes, consequences, prevention and treatment of substance abuse and addiction.

NIDA contact official: Da-Yu Wu, PhD, National Institute on Drug Abuse (NIDA), Telephone: 301-443-1887, Email: wudy@nida.nih.gov

 

------------------------------------------------

 

V. NIDA's Cutting Edge Basic Research Awards (CEBRA R21) CEBRA PAR-12-086

NIDA's Cutting Edge Basic Research Awards (CEBRA R21) is a continuing program to foster highly innovative, novel or conceptually creative research that advances our understanding of drug abuse and addiction and how to prevent and treat them.  CEBRA supports research that is high-risk and potentially high-impact that is underrepresented or not included in NIDA's current portfolio.  The proposed research should: (1) test a highly novel and significant hypothesis which, if confirmed, would have substantial impact on current thinking; and/or (2) develop or adapt innovative techniques or methods applicable to addiction research.

Next two receipt dates:  August 20th and December 19th.

For further information, see CEBRA PAR-12-086 or contact Susan Volman, PhD., svolman@nida.nih.gov

-----------------------

 

VI. Early Career Award in Chemistry of Drug Abuse and Addiction (ECHEM)  (R21/R33)

PAR-13-350

 

This announcement is intended to encourage early career chemists (or chemists new to NIH) to develop probes that aid basic research investigations on drug abuse and/or identify new or better templates as lead compounds with potential for conducting structure activity relationship (SAR)-function studies. Importantly, this includes the identification of new chemical entities (NCEs) with therapeutic potential for drug abuse and addiction. Applicants responding to this FOA should explain their rationale for the proposed work, the inclusion of pharmacologic assessments, and the relationship of the research proposed in the context of a broader medications development pipeline (e.g., Target Identification > Probe/ligand screening > Synthesis of ligands > Assay development > Proof of concept > Lead optimization, etc.).

 

For further information contact

 

Kristopher J. Bough, Ph.D.

Division of Basic Neuroscience and Behavioral Research

National Institute on Drug Abuse (NIDA)

Telephone: 301-443-9800

Email: boughk@mail.nih.gov

  

-----------------

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to istserv@list.nih.govmailto:listserv@list.nih.gov,

 Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov     301-435-1309

 

 

No comments:

Post a Comment